Kymera Therapeutics, Inc. · NASDAQ:KYMR
Booth Bruce sold 31,798 Kymera Therapeutics, Inc. shares (Form 4)
Traded Jun 22, 2026 · Filed Jun 22, 2026
On Jun 22, 2026, Booth Bruce (Director) sold 31,798 Kymera Therapeutics, Inc. shares at an average US$103.75 for US$3.3M under a trading plan, leaving 613,762 shares. Filed Jun 22, 2026 (Form 4).
- Sold
- 31,798 shares
- Price
- US$103.75 average (US$103.42 to US$104.38)
- Value
- US$3.3M
- Holding after
- 613,762 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | Common Stock | Sale | 18,313 | US$103.42 | 3,472,340 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 9,584 | US$104.38 | 3,462,756 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 2,560 | US$103.42 | 615,103 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 1,341 | US$104.38 | 613,762 | Indirect |
Source
Related
- Kymera Therapeutics, Inc.
- Booth Bruce
- Kymera Therapeutics, Inc. shareholders
- Form 4/A · Booth Bruce · Jul 2, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026